Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity

Oncogene

Volumn 34, Issue 49, 2015, Pages 5960-5970

  Cao, K ^a   Wang, G ^a   Li, W ^a   Zhang, L ^b,c   Wang, R ^d   Huang, Y ^a   Du, L ^a   Jiang, J ^e   Wu, C ^e   He, X ^e   Roberts, A I ^b   Li, F ^a   Rabson, A B ^b   Wang, Y ^a   Shi, Y ^a,b,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CHILD HEALTH INSTITUTE OF NEW JERSEY   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; EARLY GROWTH RESPONSE FACTOR 2; FAS LIGAND; HISTONE DEACETYLASE INHIBITOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT1; TRICHOSTATIN A; UNCLASSIFIED DRUG; ANTIBODY; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FASL PROTEIN, MOUSE; HYDROXAMIC ACID; NFATC2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENTIATION; GENE MUTATION; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL DEATH; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CTLA-4 ANTIGEN; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MELANOMA, EXPERIMENTAL; MICE; NFATC TRANSCRIPTION FACTORS;

EID: 84949322531     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.46     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 2006; 86: 231-245.
3. Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004; 5: 141-149.
4. Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC et al. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood 2008; 112: 4746-4754.
5. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
6. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
7. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
8. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-1366.
9. Shi YF, Sahai BM, Green DR. Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature 1989; 339: 625-626.
10. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373: 444-448.
11. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935-946.
12. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51.
13. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 2006; 66: 11298-11304.
14. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000; 60: 5165-5170.
15. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-5552.
16. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004; 101: 18030-18035.
17. Marks PA, Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005; 4: 549-551.
18. Maecker HL, Yun Z, Maecker HT, Giaccia AJ. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2002; 2: 139-148.
19. Brunner T, Yoo NJ, LaFace D, Ware CF, Green DR. Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. Int Immunol 1996; 8: 1017-1026.
20. Vaux DL. Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci USA 1993; 90: 786-789.
21. Jacobson MD. Reactive oxygen species and programmed cell death. Trends Biochem Sci 1996; 21: 83-86.
22. Colotta F, Polentarutti N, Sironi M, Mantovani A. Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J Biol Chem 1992; 267: 18278-18283.
23. Jaattela M. Escaping cell death: survival proteins in cancer. Exp Cell Res 1999; 248: 30-43.
24. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev 2003; 193: 70-81.
25. Cantrell D. T cell antigen receptor signal transduction pathways. Annu Rev Immunol 1996; 14: 259-274.
26. Wang R, Zhang L, Yin D, Mufson RA, Shi Y. Protein kinase C regulates Fas (CD95/APO-1) expression. J Immunol 1998; 161: 2201-2207.
27. Manicassamy S, Sun Z. The critical role of protein kinase C-theta in Fas/Fas ligandmediated apoptosis. J Immunol 2007; 178: 312-319.
28. Rengarajan J, Mittelstadt PR, Mages HW, Gerth AJ, Kroczek RA, Ashwell JD et al. Sequential involvement of NFAT and Egr transcription factors in FasL regulation. Immunity 2000; 12: 293-300.
29. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998; 188: 2033-2045.
30. Liu F, Bardhan K, Yang D, Thangaraju M, Ganapathy V, Waller JL et al. NF-kappaB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression. J Biol Chem 2012; 287: 25530-25540.
31. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784.
32. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18: 206-213.
33. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124: 30-39.
34. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-675.
35. Moreira JM, Scheipers P, Sorensen P. The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 2003; 3: 30.
36. Dangond F, Gullans SR. Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate. Biochem Biophys Res Commun 1998; 247: 833-837.
37. Devadas S, Das J, Liu C, Zhang L, Roberts AI, Pan Z et al. Granzyme B is critical for T cell receptor-induced cell death of type 2 helper T cells. Immunity 2006; 25: 237-247.
38. Xu G, Shi Y. Apoptosis signaling pathways and lymphocyte homeostasis. Cell Res 2007; 17: 759-771.
39. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71: 1263-1271.
40. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117: 1137-1146.
41. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
42. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett 2009; 277: 8-21.
43. Bolger TA, Yao TP. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J Neurosci 2005; 25: 9544-9553.
44. Dequiedt F, Kasler H, Fischle W, Kiermer V, Weinstein M, Herndier BG et al. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 2003; 18: 687-698.
45. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997; 15: 707-747.
46. Merion RM, White DJ, Thiru S, Evans DB, Calne RY. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med 1984; 310: 148-154.
47. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-1738.
48. Tanaka T, Takahara S, Hatori M, Suzuki K, Wang J, Ichimaru N et al. A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine. Cancer Lett 2002; 181: 165-171.
49. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534.
50. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-465.